Loading
A phase 3 trial of Melphalan in melanoma and uveal melanoma, run by Delcath Systems Inc., active and no longer recruiting.
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma is a phase 3 interventional study registered as NCT05022901 by Delcath Systems Inc., with 30 participants planned, started 2022-06-10 and due to reach its primary completion in 2024-03-01. Interventions recorded: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS). Conditions listed: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Delcath Systems, Melphalan (including hepatic delivery system).
Shares Delcath Systems, Percutaneous hepatic perfusion (chemosaturation), Melphalan (including hepatic delivery system), Uveal melanoma.
Shares Percutaneous hepatic perfusion (chemosaturation), Uveal melanoma.
Shares Delcath Systems, Uveal melanoma.
Shares Uveal melanoma, Melanoma.
Shares Uveal melanoma, Melanoma.
Shares Uveal melanoma, Melanoma.
Shares Percutaneous hepatic perfusion (chemosaturation), Melphalan (including hepatic delivery system), Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/